* Q3e: soft growth but GM improvements * Minor estimate cuts on FX and product mix * Trading at '26e...
Redeye believes gene therapy is an interesting area for imlifidase.
Redeye provides a comment on the Q3 trading update from Cheffelo, released this morning.
Redeye leaves a short comment following OncoZenge’s announcement that UCLA has enrolled the first pa...
Redeye updates its estimates and fair value range following Enviro’s rights issue, where we have als...
* We lift '26e EBIT by 4% on a higher subscription base * 30% '25e-'28e EBIT CAGR driven by Senior s...
Mer om Envar Envar: Från outsourcing till eget spelsläpp Publicerad2025.
Redeye comments on the rights issue announced today and the new study design.
Redeye provides an update following Guard Therapeutics’ announcement of new encouraging results from...
Redeye provides its initial comments on Xspray following last night’s press release confirming a Com...
Redeye takes a positive stance towards Addnode’s acquisition of SolidCAD.
* Q3'25e organic sales growth of 28% y-o-y * We lower EBITDA on customer mix * FVR of SEK 30-45 reit...
Flexion’s shares are down more than 15% following a report by the newspaper "Affärsvärlden" about a ...
Redeye comments on Invisio’s preliminary announcement of Q3-results which were lower than expected o...
Redeye briefly comments on Cinclus’ announcement that the first patient has been dosed in its pivota...
* Report out on 17 October * Q3e sales of SEK 50m, +23% y-o-y, EBIT SEK 16m (9m) * Q3 rebound expect...
Redeye provides a preview of SSH’s Q3 results, set to be released on 23 October.
Xplora's monthly subscriptions update shows that the Xplora Kids subscriber base for Q3 2025 amounte...
Redeye briefly comments on Guard Therapeutics announcing additional encouraging data from its comple...
Alisa Bank announced a collaboration with Nordea, to provide financing services for its entrepreneur...
